Literature DB >> 8786626

[In vitro and in vivo antibacterial activities of sulopenem, a new penem antibiotic].

A Komoto1, M Otsuki, T Nishino.   

Abstract

The in vitro and in vivo antibacterial activities of sulopenem, a new penem, were evaluated in comparison with imipenem (IPM), meropenem (MEPM), ceftazidime (CAZ) and flomoxef (FMOX). Sulopenem had broad and potent antibacterial spectra against Gram-positive and Gram-negative bacteria, including Enterococcus faecalis, Proteus vulgaris, Morganella morganii, Enterobacter spp. and Citrobacter freundii. Sulopenem showed concentration-dependent bactericidal activities against Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae and Acinetobacter calcoaceticus. Morphological observation using phase-contrast microscope revealed that sulopenem induced spherical cell formation with E. coli and K. pneumoniae at lower concentrations and bacteriolysis at higher concentrations. Therapeutic efficacies of sulopenem against systemic infections in mice were almost equal to those of imipenem against Streptococcus pneumoniae. While its therapeutic efficacies were superior to those of meropenem, ceftazidime and flomoxef against S. aureus and S. pneumoniae, they were inferior to those of imipenem/cilastatin against S. aureus, K. pneumoniae and A. calcoaceticus.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8786626

Source DB:  PubMed          Journal:  Jpn J Antibiot        ISSN: 0368-2781


  1 in total

Review 1.  Sulopenem: An Intravenous and Oral Penem for the Treatment of Urinary Tract Infections Due to Multidrug-Resistant Bacteria.

Authors:  George G Zhanel; Marianna Pozdirca; Alyssa R Golden; Courtney K Lawrence; Sheryl Zelenitsky; Liam Berry; Frank Schweizer; Denice Bay; Heather Adam; Michael A Zhanel; Philippe Lagacé-Wiens; Andrew Walkty; Neal Irfan; Kurt Naber; Joseph P Lynch; James A Karlowsky
Journal:  Drugs       Date:  2022-03-16       Impact factor: 9.546

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.